GlassScriptPhysician profile
Matthew Downey
NPI 1215662184
$2,126.44
in general payments reported to CMS, 2019-2025
20 companies · $760 in 2025
The $760 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $206 · 2024: $1,160 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $496.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $416.42 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $198.63 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.72 | 2023-2025 | Xifaxan |
| Pfizer INC. | $168.05 | 2023-2025 | |
| Glaxosmithkline, LLC. | $129.33 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merit Medical Systems INC | $128.06 | 2025 | Esophyx |
| Indivior INC. | $93.23 | 2023-2024 | Sublocade |
| Exact Sciences Corporation | $72.03 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $33.55 | 2024-2025 | Mounjaro, Zepbound |
| Eisai INC. | $29.15 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.46 | 2025 | Spravato |
| Boston Scientific Corporation | $22.79 | 2025 | Intracept |
| Amgen INC. | $19.75 | 2024 | Otezla, Repatha |
| Biogen, INC. | $19.60 | 2024 | Spinraza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.55 | 2024 | Octrode |
| Dexcom, INC. | $19.42 | 2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $19.06 | 2023 | Hetlioz |
| Idorsia Pharmaceuticals US INC | $15.11 | 2023 | Quviviq |
| Astellas Pharma US INC | $14.25 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Downey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.